With network analyses taking an astonishing flight in psychiatry, we recommend cautious application of group-level network density as a prognostic marker. Crucial steps to be taken by the field include further replication studies as well as indepth psychometric evaluation of the reliability and clinical correlates of network parameters.
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Pediatric Use of Antipsychotic Medications Before and After Medicaid Peer Review Implementation
In response to the growing cardiometabolic safety concerns about the use of atypical antipsychotic (AAP) medications in children, 1,2 several state Medicaid agencies have adopted a novel, more clinically nuanced and individualized approach to reviewing the appropriateness of AAP use, namely, peer review prior authorization (PA) policies. 3 Physicians must receive preapproval through contracted clinicians (peer reviewers) to prescribe AAPs to certain-aged children. We assessed the effect of peer review PA policies on AAP use among Medicaid-insured youth according to age restriction criteria. We used an interrupted time-series design to assess monthly and quarterly use of AAPs across 36 months, including 12-month prepolicy, 12-month transition, and 12-month postpolicy analysis. 4 The unit of analysis was child with any AAP dispensing. The 12-month transition period represented 6 months before and after the policy implementation date in each state. The study was an extension of an interagency agreement between the Centers for Medicare & Medicaid and the US Food and Drug Administration's Safe Use Initiative. The US Food and Drug Administration Research in Human Subjects Committee determined that the study does not qualify as human research (records review with no identifiers). In multivariable logistic regression models with generalized estimating equations, we added interaction terms for time period and age group to assess whether changes in AAP use differed by age group in the postpolicy vs prepolicy periods.
Results | Compared with the prepolicy period, AAP prevalence after policy implementation decreased significantly from 0.25% to 0.17% (odds ratio [OR], 0.68; 95% CI, 0.64-0.72) for children younger than 8 years in state A, from 0.09% to 0.05% (OR, 0.57; 95% CI, 0.50-0.66) for children younger than 6 years in state B, from 0.09% to 0.07% (OR, 0.76; 95% CI, 0.69-0.84) for children younger than 6 years in state C, and from 0.03% to 0.02% (OR, 0.64; 95% CI, 0.46-0.88) for children younger than 5 years in state D (Table and Figure) .
Among older youth (lacking peer review), AAP use increased significantly in states A, B, and C. Although there was a decrease in AAP use in both older (5-17 years) and younger (<5 years) groups in state D, the decrease was significantly greater only in children younger than 5 years (interaction P = .03).
Discussion | With the implementation of the peer review PA policies instituted in 4 geographically diverse state Medicaid programs, AAP use declined substantially in children younger than 5 to 8 years. The policy generally had little or no discernible effect on AAP use in older youth, possibly reflecting evidencebased practice.
These findings are consistent with recent national estimates suggesting that the rapid increase in AAP use among publicly insured young children had stabilized since 2008.
5 However, challenges exist, such as growing use of complex AAP regimens and low uptake of recommended cardiometabolic monitoring. 5 Educationally oriented peer review, as demonstrated in state D, may account for spillover effects among older youth who were not similarly monitored.
6
The study is limited by the inability to control for all the external factors that may affect prescribing patterns. Moreover, the findings may not be nationally representative and do not imply clinical appropriateness. Nonetheless, our study reports significant decreases in AAP use among Medicaidinsured young children following the implementation of these peer review PA policies and motivates research on the longterm consequences of these policies on clinical outcomes. 
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Age group was defined according to the age restriction criteria set by the peer review prior authorization policies for atypical antipsychotic prescribing to Medicaid-insured youth in the 4 study states. In state A, the policy applied to children younger than 8 years; in states B and C, children younger than 6 years; and in state D, children younger than 5 years. preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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COMMENT & RESPONSE
Equivalence? Clarifications Required
To the Editor Barlow and colleagues 1 compared a unified cognitive behavior therapy protocol with single-disorder cognitive behavior therapy protocols in anxiety disorders. Unified protocols for broader classes of disorders represent a promising approach. However, several issues need to be clarified. First, in the study protocol, the authors 1 listed 4 measures as primary outcomes without defining 1 of them as primary. Numerous primary outcomes imply several problems, including ambiguity of results, problems for power analysis, and type I error inflation. 2 In the article, however, the authors specify only Anxiety Disorders Interview Schedule clinical severity ratings as the primary outcome.
1 Second, the value of an equivalence study depends on how well the equivalence margin can be justified.
3 The authors used a difference of 0.75 clinical severity rating units as an equivalence margin without, however, stringently deriving it from the cited references. Furthermore, it is not clear whether this difference corresponds to a large, medium, or small effect size. The authors are asked to report the margin in terms of effect size. Third, the authors consider a sample size of 91 patients per active treatment as sufficient to demonstrate equivalence with a power of 0.80 using a margin of 0.75 clinical severity rating units.
1 It is not clear how they determined the sample size. The authors are asked to clarify this. Admittedly, the empirical between-group effect sizes were small. Fourth, the statistical analysis strategy for testing equivalence was not specified in the study protocol. It is not clear, for example, whether the 2 one-sided test procedure was applied.
3 Fifth, the treatments in both the Unified Protocol and single-disorder protocols were carried out by the same therapists, leaving room for therapist allegiance effects. 4 Furthermore, it is not clear by whom the therapists were trained. If they were trained by some of the study authors, supervisor allegiance effects cannot be ruled out as well. 4,5 Thus, internal validity of the study may be affected. Sixth, regarding treatment fidelity, it is not clear who rated the sessions, which instrument was used, and whether the raters were blinded to study conditions. Seventh, the authors did not carry out sensitivity analyses by anxiety disorder. Thus, it is not clear whether the treatments are equally efficacious in the specific anxiety disorders. It is not clear whether the conclusion of equivalence holds if the issues listed above are taken into account.
Falk Leichsenring, DSc
